Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.
Level 5 - mechanism / opinion, no new human data
Clinical practice guideline synthesizing evidence via expert consensus panel
PubMed 26444994 · doi:10.1210/jc.2015-2236
What was done
An Endocrine Society task force consisting of six experts, a methodologist, and a medical writer developed a clinical practice guideline for managing menopause symptoms using the GRADE framework. The task force commissioned three systematic reviews and evaluated existing meta-analyses and randomized trials. Drafts were finalized through panel consensus and reviewed by several international endocrine and menopause societies.
What was found
The abstract reports no numerical values, effect sizes, or statistical estimates. It reports that menopausal hormone therapy is the most effective treatment for vasomotor and climacteric symptoms, with benefits generally exceeding risks in symptomatic women aged under 60 years or within 10 years of menopause onset. It reports that evidence does not support hormone therapy for the prevention of coronary heart disease, breast cancer, or dementia. Low-dose vaginal estrogen and ospemifene were identified as effective options for genitourinary syndrome of menopause, alongside non-hormonal alternatives and lifestyle measures.
Why it matters
This guideline provides consensus recommendations to help clinicians individualize menopausal symptom management according to patient age, time since menopause, and personal risk profile.
Limits
The abstract provides no quantitative data, event rates, or confidence intervals. Specific dosages, treatment durations, and detailed safety profiles are not reported in the abstract.
Cited by
- supports Menopausal hormone replacement therapy improves sleep, mood, and thermoregulatory vasomotor symptoms such as hot flashes and night sweats.